logo
Plus   Neg
Share
Email

Boehringer, Lilly Report Positive Top-line Phase III Empagliflozin Results

Boehringer Ingelheim and Eli Lilly and Co. (LLY) announced top-line results for four completed Phase III trials for empagliflozin, an investigational sodium glucose co-transporter-2 or SGLT-2 inhibitor being studied for type 2 diabetes or T2D treatment.

The company said that incidence of adverse events was similar for placebo, empagliflozin 10mg and 25mg, while genital infections occurred more often with empagliflozin compared with placebo. This safety information is consistent with findings reported in the Phase II trial results for empagliflozin.

Empagliflozin is being investigated in adults with T2D in a Phase III study program, which would enroll more than 14,500 patients. Totally, this program consists of eight multinational trials, including a large cardiovascular outcome trial. The pivotal studies for empagliflozin completed in 2012, and Boehringer Ingelheim and Lilly anticipate filing for regulatory review in the U.S., Europe and Japan in 2013. Boehringer Ingelheim and Lilly intend to present detailed data disclosures for many of these studies at scientific medical meetings and publications in 2013 and 2014.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chipotle Mexican Grill Inc. is introducing a new protein to its menu, Carne Asada, starting this week. Carne Asada is Chipotle's newest protein addition since it reintroduced chorizo in September 2018. The Mexican food chain said that the new steak option will be available at its restaurants nationwide from Thursday, September 19, 2019. Pizza Hut has partnered with Cheez-It to launch a new item to its menu - the Stuffed Cheez-It Pizza. The pizza chain, a subsidiary of Yum! Brands, said that the new item combines Pizza Hut pizza and the Cheez-It cheese snack. Stuffed Cheez-It Pizza will be available on Pizza Hut menus nationwide for a limited-time. Pizza Hut is the official pizza sponsor of the NFL and NCAA. The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world.
Follow RTT